Alterations of global histone H3K9 and H3K27 methylation levels in bladder cancer

Urologia Internationalis

Volumn 93, Issue 1, 2014, Pages 113-118

  Ellinger, Jörg ^a   Bachmann, Anne ^a   Göke, Friederike ^a   Behbahani, Turang E ^a   Baumann, Claudia ^a   Heukamp, Lukas C ^b   Rogenhofer, Sebastian ^a   Müller, Stefan C ^a  

^a UNIVERSITY HOSPITAL BONN   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Bladder cancer; H3K27; H3K9; Histone; Methylation

Indexed keywords

HISTONE H3; HISTONE H3K27; HISTONE H3K9; UNCLASSIFIED DRUG; HISTONE;

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER SPECIFIC SURVIVAL; CONTROLLED STUDY; CYSTECTOMY; FEMALE; HISTONE METHYLATION; HISTONE MODIFICATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; METASTASIS; MUSCLE INVASIVE BLADDER CANCER; NON MUSCLE INVASIVE BLADDER CANCER; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; TISSUE MICROARRAY; TRANSCRIPTION REGULATION; UROTHELIUM; BLADDER METASTASIS; CANCER GENETICS; CANCER STAGING; LYMPH NODE METASTASIS; MOLECULAR PATHOLOGY; TRANSITIONAL CELL CARCINOMA; BLADDER TUMOR; METABOLISM; METHYLATION; MIDDLE AGED; PATHOLOGY; PROGNOSIS; TUMOR RECURRENCE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HISTONES; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; MALE; METHYLATION; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; TISSUE ARRAY ANALYSIS; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 84904389357     PISSN: 00421138     EISSN: 14230399     Source Type: Journal    
DOI: 10.1159/000355467     Document Type: Article

References (32)

1. Jeon SH, Jeon SH, Chang SG: Clinical prognostic factors for radical cystectomy in bladder cancer. Cancer Res Treat 2005; 37: 48-53
2. Altieri VM, Castellucci R, Palumbo P, Verratti V, Sut M, Olivieri R, Manco R, Ricciardulli S, Nicolai M, Criniti P, Tenaglia RL: Recurrence and progression in non-muscleinvasive bladder cancer using EORTC risk tables. Urol Int 2012; 89: 61-66
3. Dudziec E, Goepel JR, Catto JW: Global epigenetic profiling in bladder cancer. Epigenomics 2011; 3: 35-45
4. Kouzarides T: Chromatin modifications and their function. Cell 2007; 128: 693-705
5. Greer EL, Shi Y: Histone methylation: A dynamic mark in health, disease and inheritance. Nat Rev Genet 2012; 13: 343-357
6. Seligson DB, Horvath S, Shi T, Yu H, Tze S, Grunstein M, Kurdistani SK: Global histone modification patterns predict risk of prostate cancer recurrence. Nature 2005; 435: 1262-1266
7. Schneider AC, Heukamp LC, Rogenhofer S, Fechner G, Bastian PJ, von Ruecker A, Müller SC, Ellinger J: Global histone H4K20 trimethylation predicts cancer-specific survival in patients with muscle-invasive bladder cancer. BJU Int 2011; 108:E290-E296
8. Barbisan F, Mazzucchelli R, Santinelli A, Stramazzotti D, Scarpelli M, Lopez-Beltran A, Cheng L, Montironi R: Immunohistochemical evaluation of global DNA methylation and histone acetylation in papillary urothelial neoplasm of low malignant potential. Int J Immunopathol Pharmacol 2008; 21: 615-623
9. Cheung WL, Albadine R, Chan T, Sharma R, Netto GJ: Phosphorylated H2AX in noninvasive low grade urothelial carcinoma of the bladder: Correlation with tumor recurrence. J Urol 2009; 181: 1387-1392
10. Rogenhofer S, Miersch H, Göke F, Kahl P, Wieland WF, Hofstädter F, Kristiansen G, von Ruecker A, Müller SC, Ellinger J: Histone methylation Defines an epigenetic entity in penile squamous cell carcinoma. J Urol 2013; 189: 1117-1122
11. Ellinger J, Kahl P, von Der Gathen J, Rogenhofer S, Heukamp LC, Gütgemann I, Walter B, Hofstädter F, Büttner R, Müller SC, Bastian PJ, von Ruecker A: Global levels of histone modifications predict prostate cancer recurrence. Prostate 2010; 70: 61-69
12. Ellinger J, Kahl P, von Der Gathen J, Heukamp LC, Gütgemann I, Walter B, Hofstädter F, Bastian PJ, von Ruecker A, Müller SC, Rogenhofer S: Global histone H3K27 methylation levels are different in localized and metastatic prostate cancer. Cancer Invest 2012; 30: 92-97
13. Pellakuru LG, Iwata T, Gurel B, Schultz D, Hicks J, Bethel C, Yegnasubramanian S, De Marzo AM: Global levels of H3K27me3 track with differentiation in vivo and are deregulated by MYC in prostate cancer. Am J Pathol 2012; 181: 560-569
14. Rogenhofer S, Kahl P, Holzapfel S, von Ruecker A, Mueller SC, Ellinger J: Decreased levels of histone H3K9me1 indicate poor prognosis in patients with renal cell carcinoma. Anticancer Res 2012; 32: 879-886
15. Rogenhofer S, Kahl P, Mertens C, Hauser S, Hartmann W, Büttner R, Müller SC, von Ruecker A, Ellinger J: Global histone H3 lysine 27 (H3K27) methylation levels and their prognostic relevance in renal cell carcinoma. BJU Int 2012; 109: 459-465
16. Shen Y, Guo X, Wang Y, Qiu W, Chang Y, Zhang A, Duan X: Expression and significance of histone H3K27 demethylases in renal cell carcinoma. BMC Cancer 2012; 12: 470
17. Seligson DB, Horvath S, McBrian MA, Mah V, Yu H, Tze S, Wang Q, Chia D, Goodglick L, Kurdistani SK: Global levels of histone modifications predict prognosis in Different cancers. Am J Pathol 2009; 174: 1619-1628
18. Park YS, Jin MY, Kim YJ, Yook JH, Kim BS, Jang SJ: The global histone modification pattern correlates with cancer recurrence and overall survival in gastric adenocarcinoma. Ann Surg Oncol 2008; 15: 1968-1976
19. Song JS, Kim YS, Kim DK, Park SI, Jang SJ: Global histone modification pattern associated with recurrence and disease-free survival in non-small cell lung cancer patients. Pathol Int 2012; 62: 182-190
20. Tamagawa H, Oshima T, Numata M, Yamamoto N, Shiozawa M, Morinaga S, Nakamura Y, Yoshihara M, Sakuma Y, Kameda Y, Akaike M, Yukawa N, Rino Y, Masuda M, Miyagi Y: Global histone modification of H3K27 correlates with the outcomes in patients with metachronous liver metastasis of colorectal cancer. Eur J Surg Oncol 2013; 39: 655-661
21. Holm K, Grabau D, Lövgren K, Aradottir S, Gruvberger-Saal S, Howlin J, Saal LH, Ethier SP, Bendahl PO, Stål O, Malmström P, Fernö M, Rydén L, Hegardt C, Borg Å, Ringnér M: Global H3K27 trimethylation and EZH2 abundance in breast tumor subtypes. Mol Oncol 2012; 6: 494-506
22. Kurdistani SK: Histone modifications in cancer biology and prognosis. Prog Drug Res 2011; 67: 91-106
23. Fillingham J, Keogh MC, Krogan NJ: GammaH2AX and its role in DNA double-strand break repair. Biochem Cell Biol 2006; 84: 568-577
24. Günlüsoy B, Deǧirmenci T, Arslan M, Nergiz N, Minareci S, Ayder AR: Recurrence and progression of T1G3 transitional cell carcinoma of the bladder treated with intravesical bacillus Calmette-Guérin. Urol Int 2005; 75: 107-113
25. Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Bohle A, Palou-Redorta J, Roupret M: EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update. Eur Urol 2011; 59: 997-1008
26. van Den Bosch S, Alfred Witjes J: Long-Term cancer-specific survival in patients with highrisk, non-muscle-invasive bladder cancer and tumour progression: A systematic review. Eur Urol 2011; 60: 493-500
27. Barski A, Cuddapah S, Cui K, Roh TY, Schones DE, Wang Z, Wei G, Chepelev I, Zhao K: High-resolution profiling of histone methylations in the human genome. Cell 2007; 129: 823-837
28. Choi SH, Worswick S, Byun HM, Shear T, Soussa JC, Wolff EM, Douer D, Garcia-Manero G, Liang G, Yang AS: Changes in DNA methylation of tandem DNA repeats are different from interspersed repeats in cancer. Int J Cancer 2009; 125: 723-729
29. Seifert HH, Schmiemann V, Mueller M, Kazimirek M, Onofre F, Neuhausen A, Florl AR, Ackermann R, Boecking A, Schulz WA, Grote HJ: In situ detection of global DNA hypomethylation in exfoliative urine cytology of patients with suspected bladder cancer. Exp Mol Pathol 2007; 82: 292-297
30. Schuster-Bockler B, Lehner B: Chromatin organization is a major influence on regional mutation rates in human cancer cells. Nature 2012; 488: 504-507
31. Tian X, Zhang S, Liu HM, Zhang YB, Blair CA, Mercola D, Sassone-Corsi P, Zi X: Histone lysine-specific methyltransferases and demethylases in carcinogenesis: New targets for cancer therapy and prevention. Curr Cancer Drug Targets 2013; 13: 558-579
32. Arisan S, Buyuktuncer ED, Palavan-Unsal N, Caskurlu T, Cakir OO, Ergenekon E: Increased expression of EZH2, a polycomb group protein, in bladder carcinoma. Urol Int 2005; 75: 252-257.